- My News
- All News
- Most Popular
"Based on previous studies that demonstrate the benefits of iNO in oxygenation and immune response, INOpulse has the potential to be used as a viable treatment option for COVID-19," said the treating physician, Roger Alvarez, DO, MPH, Assistant Professor, University of Miami School of Medicine. "The cardiopulmonary benefit demonstrated by INOpulse in various indications provides the potential to prevent deterioration in patients with COVID-19, allowing ventilators to be preserved for the most critically ill. INOpulse's ease of administration could significantly decrease the burden on therapists and nurses as they combat this pandemic with constrained resources."
COVID-19 is caused by the SARS-CoV-2 virus, which is approximately 82% identical to the severe acute respiratory syndrome related coronavirus (SARS-CoV) that caused a global outbreak between 2003 and 2004¹. Prior studies have shown that nitric oxide (NO) could provide benefit in treating SARS-CoV by preventing viral replication², improving arterial oxygenation, reducing the need for ventilation support and preventing the proliferation of lung infiltrates³. Based on the genetic similarities between the two coronaviruses, the historical data in SARS-CoV support the potential for iNO to provide meaningful benefit for patients infected with COVID-19.
"We believe the first patient with COVID-19 to start treatment with INOpulse could be a critical step in the fight against this pandemic due to the therapy's potential to halt disease progression and reduce the need for ventilation support," said Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics. "Moreover, INOpulse's ability to treat patients in the outpatient setting could help alleviate the mounting impact on the capacity of hospitals and intensive care units. We will continue to collaborate with the FDA and will work diligently to make INOpulse available to more patients at more sites around the U.S. as expeditiously as possible."
Bellerophon is currently developing INOpulse for multiple unmet cardiopulmonary indications. The Company recently announced positive top-line results from its Phase 2 studies for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF) and plans to initiate a pivotal Phase 3 study in PH-PF. Bellerophon's proprietary INOpulse delivery system is portable and designed to deliver NO in a targeted, pulsatile manner that ensures accurate drug delivery and allows for use in outpatient settings outside of the hospital.
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Any statements in this press release about Bellerophon's future expectations, plans and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company's clinical trials and expectations regarding the sufficiency of the Company's cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words "anticipate," "believe," "continue," "contemplate," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary or interim results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, the FDA's substantial discretion in the approval process, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent Bellerophon's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.
|Brian Ritchie||Julie Normart|
|(212) 915-2578||(559) 974-3245|
Did you like this article?